Semaglutide · research summary

GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.

HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Retrospective cohort study using the TriNetX Global Collaborative Network
“We conducted a retrospective cohort study using the TriNetX Global Collaborative Network to identify adult patients (≥18 years) who underwent primary THA (current procedural terminology code 27130) between January 2015 and December 2025.”

Subjects

Adult patients undergoing primary total hip arthroplasty with either active GLP-1 RA prescription or history of bariatric surgery within 18 months prior
“Patients were divided into 2 cohorts: those with an active prescription for a GLP-1 RA (semaglutide, dulaglutide, liraglutide, tirzepatide, exenatide, albiglutide, or lixisenatide) within 18 months prior to the index THA procedure (N = 6877) or those with a history of bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, and biliopancreatic diversion) within 18 months prior to the index THA procedure (N = 3960).”

Sample size

2640 patients in each cohort after propensity-score matching
“After propensity-score matching, 2640 patients were included in each cohort (Figure 1).”

Duration

Outcomes assessed at 1 to 90 days and 91 days to 1 year postoperatively
“Outcomes included revision THA, dislocation/instability, PJI, wound complications, emergency department (ED) visits, and readmission at 1 to 90 days and 91 days to 1 year postoperatively.”

Reported findings

GLP-1 RA cohort had lower risks of revision, PJI, ED visits, readmission, wound dehiscence, and dislocation within 90 days
“Within 90 days, the GLP-1 RA cohort had lower risks of revision, PJI, ED visits, readmission, wound dehiscence, and dislocation.”
GLP-1 RA patients showed lower risks of PJI, readmission, and all-cause revision at mid-term follow-up
“At mid-term follow-up, GLP-1 RA patients continued to show lower risks of PJI, readmission, and all-cause revision.”
No significant differences were observed in periprosthetic fracture or surgical site infection between groups
“Risks of periprosthetic fracture and SSI did not differ significantly between groups.”

Source: PubMed 42856761 · DOI 10.1177/15563316261492267 · all study summaries

Study type

Retrospective cohort study using the TriNetX Global Collaborative Network

“We conducted a retrospective cohort study using the TriNetX Global Collaborative Network to identify adult patients (≥18 years) who underwent primary THA (current procedural terminology code 27130) between January 2015 and December 2025.”

Subjects

Adult patients undergoing primary total hip arthroplasty with either active GLP-1 RA prescription or history of bariatric surgery within 18 months prior

“Patients were divided into 2 cohorts: those with an active prescription for a GLP-1 RA (semaglutide, dulaglutide, liraglutide, tirzepatide, exenatide, albiglutide, or lixisenatide) within 18 months prior to the index THA procedure (N = 6877) or those with a history of bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, and biliopancreatic diversion) within 18 months prior to the index THA procedure (N = 3960).”

Reported findings

GLP-1 RA cohort had lower risks of revision, PJI, ED visits, readmission, wound dehiscence, and dislocation within 90 days

“Within 90 days, the GLP-1 RA cohort had lower risks of revision, PJI, ED visits, readmission, wound dehiscence, and dislocation.”

GLP-1 RA patients showed lower risks of PJI, readmission, and all-cause revision at mid-term follow-up

“At mid-term follow-up, GLP-1 RA patients continued to show lower risks of PJI, readmission, and all-cause revision.”

No significant differences were observed in periprosthetic fracture or surgical site infection between groups

“Risks of periprosthetic fracture and SSI did not differ significantly between groups.”